Author

K. Esser-Nobis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Assay:protein structure· 1 Assay:proteomics· 1

Frequent Co-Authors

M. Gale· 2 shared T.-Y. Hsiang· 2 shared A. Chen· 1 shared A. E. L. Stone· 1 shared A. Forero· 1 shared A. Josephson-Day· 1 shared A. M. Kell· 1 shared A. Pong· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

M. Gale

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation

O. Colasanti, R. Burm, H.-E. Huang, T. Riedl, J. Traut, N. Gillich, T.-F. Li, L. Corneillie, S. Faure-Dupuy, O. Gruenvogel, D. Heide, J.-Y. Lee, C. S. Tran, U. Merle, M. Chironna, , V. Lohmann

This study compares HAV and HCV infections in vivo and in vitro, revealing that HAV induces an innate immune response via MDA5/LGP2 with limited protease-mediated suppression, while HCV activates TLR3 without TRIF cleavage.

bioRxiv · Nov 7, 2022 · PreprintImmunology

Endomembrane targeting of human OAS1 p46 augments antiviral activity

F. W. Soveg, J. Schwerk, N. S. Gokhale, K. Cerosaletti, J. R. Smith, E. Pairo-Castineira, A. M. Kell, A. Forero, S. A. Zaver, K. Esser-Nobis, J. Roby, T.-Y. Hsiang, S. Ozarkar, J. M. Clingan, E. T. McAnarney, , R. Savan

This study shows that the OAS1 p46 isoform, targeted to the endomembrane system, enhances antiviral activity against RNA viruses and is associated with COVID-19 severity.

bioRxiv · Apr 21, 2021Immunology

De novo design of ACE2 protein decoys to neutralize SARS-CoV-2

T. W. Linsky, R. Vergara, N. Codina, J. W. Nelson, M. J. Walker, W. Su, T.-Y. Hsiang, K. Esser-Nobis, K. Yu, Y. J. Hou, T. Priya, M. Mitsumoto, A. Pong, U. Y. Lau, M. L. Mason, , D.-A. Silva

The paper designs de novo ACE2 protein decoys to neutralize SARS-CoV-2 by blocking viral entry, showing high affinity and potent in vitro inhibition.

bioRxiv · Aug 3, 2020Biochemistry